Tirzepatide

Dual GIP and GLP-1 receptor agonist

Ficha técnicaLZH-002

Código: GIP / GLP-1
Fórmula: C225H348N48O68
Masa molecular: 4813.5 Da
Semivida: ~120 h (≈ 5 days)
Vía de investigación: Subcutaneous (research)
Dianas moleculares: GIPR · GLP-1R
Descubrimiento / divulgación: Disclosed 2018, Eli Lilly
Pureza objetivo: ≥ 98%
Almacenamiento recomendado: −20 °C, protegido de la luz. De 2 a 8 °C tras la reconstitución.

Sinónimos

LY3298176, Mounjaro, Zepbound

Aspecto

White lyophilized powder

Solubilidad

Soluble in phosphate buffer pH 7-8

Secuencia

YAibEGTFTSDYSIaibLDKIAQK(γE-2xOEG-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH2

Analistas revisando el cromatograma de HPLC del lote actual — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Técnico supervisando un reactor de acero inoxidable durante el escalado — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Descripción general

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, a 39 amino acid synthetic peptide that activates two incretin pathways simultaneously.

Farmacología y mecanismo

GIP receptor co-activation enhances insulin secretion, improves lipid metabolism and modulates adipose tissue, stacking with GLP-1 effects for stronger metabolic and body weight outcomes.